Clinical trial
A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma
To show that progression-free survival in the pazopanib group is not inferior to that in the doxorubicin group
| Category | Value |
|---|---|
| Study start date | 2012-06-04 |